Erratum : Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria (BMC Musculoskelet Disord. (2016) 17:358 DOI: 10.1186/s12891-016-1207-4);Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: Current practice of bDMARD therapy in rheumatoid arthritis in Austria

BMC Musculoskeletal Disorders

Volumn 17, Issue 1, 2016, Pages 1-1

  Rintelen, Bernhard ^a,b   Zwerina, Jochen ^c   Herold, Manfred ^d   Singer, Franz ^e   Hitzelhammer, Johann ^f   Halder, Wolfgang ^g   Eichbauer Sturm, Gabriela ^h   Puchner, Rudolf ⁱ   Stetter, Miriam ^j   Leeb, Burkhard F ^a,b,k   Böttcher, Elke ^l   Boso, Lothar ^l   Brezinschek, Hans Peter ^l   Dunky, Attila ^l   Eberl, Gabriele ^l   Ferincz, Vera ^l   Gaugg, Markus ^l   Lechner, Gudrun ^l   Mai, Harsono T H ^l   Mur, Erich ^l   Mustak Blagusz, Monika ^l   Nell Duxneuner, Valerie ^l   Österbauer, Andrea ^l   Petera, Peter ^l   Sautner, Judith ^l   Steindl, Martin ^l   Stummer, Otto ^l   Teich, Gerhard ^l   Thoma, Wolfgang ^l   Totzauer, Anna ^l   Trenkler, Andrea ^l   Vesenmayer, Armin ^l   Wolf, Jeanette ^l   more..

^a Center for Rheumatology   (Austria)

^b Karl Landsteiner Institute for Clinical Rheumatology   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e BioReg   (Austria)

^f WIENER GEBIETSKRANKENKASSE   (Austria)

^g Hospital Hochzirl   (Austria)

^h Office Based Rheumatologist   (Austria)

ⁱ Office Based Rheumatologist   (Austria)

^j Lower Austrian State Hospital Amstetten   (Austria)

^k MEDICAL UNIVERSITY OF GRAZ   (Austria)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ABSCESS; ADULT; ARTICLE; AUSTRIA; B CELL LYMPHOMA; BACTERIAL ARTHRITIS; BREAST CANCER; COMMON COLD; DAS28; DISEASE ACTIVITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EYE DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL INFECTION; HERPES SIMPLEX; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; REGISTER; REMISSION; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS DISEASE ACTIVITY INDEX; RHEUMATOID ARTHRITIS DISEASE ACTIVITY INDEX 5; RHEUMATOLOGY; SKIN ULCER; THROMBOSIS; THYROID CANCER; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VALIDITY; VERTIGO; AGED; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; GERMANY; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUSTRIA; BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GERMANY; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; REGISTRIES; TREATMENT OUTCOME;

EID: 84983341251     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-016-1270-x     Document Type: Erratum

References (43)

1. BIOREG Website [Internet. Accessed 31 May 2016]. [Website in German] Available from: http://www.bioreg.at/
2. RABBIT Website [Internet. Accessed 31 May 2016]. [Website in German and English] Available from: http://www.biologika-register.de/home/
3. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
4. Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B. Patient-centered rheumatoid arthritis disease activity assessment by a modified RADAI. J Rheumatol. 2008;35:1294-9.
5. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-45.
6. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford). 2004;43:1252-5.
7. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, American College of Rheumatology, European League Against Rheumatism, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573-86.
8. Rintelen B, Haindl PM, Sautner J, Leeb BA, Deutsch C, Leeb BF. The rheumatoid arthritis disease activity index-5 in daily use. Proposal for disease activity categories. J Rheumatol. 2009;36:918-24.
9. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:34-40.
10. Rintelen B, Sautner J, Schwarzenfeld C, Haindl PM, Leeb BA, Leeb BF. Proposals for thresholds to express improvement and detoriation in rheumatoid arthritis patients according to the RADAI-5 [Abstract]. Ann Rheum Dis Suppl. 2009;68 Suppl 3:221.
11. Rintelen B, Sautner J, Haindl P, Mai H, Brezinschek HP, Leeb BF. Remission in rheumatoid arthritis: a comparison of the 2 newly proposed ACR/EULAR remission criteria with the rheumatoid arthritis disease activity index-5, a patient self-report disease activity index. J Rheumatol. 2013;40:394-400.
12. Shahouri SH, Michaud K, Mikuls TR, Caplan L, Shaver TS, Anderson JD, et al. Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis Rheum. 2011;63:3204-15.
13. Prince FH, Bykerk VP, Shadick NA, Lu B, Cui J, Frits M, et al. Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Res Ther. 2012;14(2):R68.
14. Kearsley-Fleet L, Závada J, Hetland ML, Nordström DC, Aaltonen KJ, Listing J, EULAR Study Group for Registers and Observational Drug Studies, et al. The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. Rheumatology (Oxford). 2015;54:1074-9.
15. Uhlig T, Lie E, Norvang V, Lexberg ÅS, Rødevand E, Krøll F, et al. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study. J Rheumatol. 2016;43(4):716-23.
16. Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the German biologics register. Arthritis Res Ther. 2006;8(3):R66.
17. Initiative Arznei und Vernunft [Internet. Accessed 21 Nov 2015]. [Article in German] Available from: http://www.pharmig.at/uploads/AVLeitlinieRheumatoideArthritis-7873-DE.pdf
18. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492-509.
19. Iannone F, Gremese E, Gallo G, Sarzi-Puttini P, Botsios C, Trotta F, GISEA (Gruppo Italiano Studio Early Arthritis), et al. High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. Clin Rheumatol. 2014;33:31-7.
20. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52:53-61.
21. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70:1914-20.
22. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52(11):3403-12.
23. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258-65.
24. Michaud TL, Rho YH, Shamliyan T, Kuntz KM, Choi HK. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med. 2014;127(12):1208-32.
25. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, van der Heijde D, Winthrop K, Landewé R. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):529-35.
26. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2:CD008794.
27. Buttgereit F. Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis? Ann Rheum Dis. 2011;70:1881-3.
28. Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2015;74:415-21.
29. van der Goes MC, Jacobs JW, Boers M, Andrews T, Blom-Bakkers MA, Buttgereit F, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2010;69(6):1015-21.
30. Da Silva JAP, Jacobs JWG, Kirwan JR, Boers M, Saag KG, Ines LBS, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65(3):285-93.
31. Herold M, Eichbauer-Sturm G, Puchner R, Rintelen B, Singer F, Leeb B. Common place though not approved - Monotherapy with biologics. Data from the Austrian BIOREG registry [Abstract]. Ann Rheum Dis Suppl. 2015;74 Suppl 2:486.
32. Jørgensen TS, Kristensen LE, Christensen R, Bliddal H, Lorenzen T, Hansen MS, et al. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. Rheumatology (Oxford). 2015;54(12):2156-65.
33. Gabay C, Riek M, Scherer A, Finckh A, SCQM collaborating physicians. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Rheumatology (Oxford). 2015;54(9):1664-72.
34. van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, Swefot study group, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012;379(9827):1712-20.
35. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, TEAR Investigators, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012;64(9):2824-35.
36. Eriksson JK, Wallman JK, Miller H, Petersson IF, Ernestam S, Vivar N, van Vollenhoven RF, Neovius M. Infliximab versus Conventional Combination Treatment and 7-Year Work Loss in Early RA: Results of the Randomized Swefot Trial. Arthritis Care Res (Hoboken). 2016. doi: 10.1002/acr.22899
37. Eriksson JK, Karlsson JA, Bratt J, Petersson IF, van Vollenhoven RF, Ernestam S, et al. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. Ann Rheum Dis. 2015;74(6):1094-101.
38. Austria-Codex Fachinformation, Erscheindatum 01.01.2015, Apothekerverlag, [Internet. Accessed 30 Oct 2015]. [Website in German] Available from: http// www.apoverlag.at
39. Putrik P, Ramiro S, Kvien TK, Sokka T, Uhlig T, Boonen A, Equity in Clinical Eligibility Criteria for RA treatment Working Group. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth? Ann Rheum Dis. 2014;73(11):2010-21.
40. Vermeer M, Kievit W, Kuper HH, Braakman-Jansen LM, Bernelot Moens HJ, et al. Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry. BMC Musculoskelet Disord. 2013;14:350.
41. Moghadam MG, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M, Dutch National POET Collaboration et al. Stopping tumor necrosis factor-inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open-label controlled trial. Arthritis Rheumatol. 2016. doi: 10.1002/art.39626
42. van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, et al. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev. 2014;9:CD010455. doi: 10.1002/14651858.CD010455.pub2.
43. Fleischmann R, Kavanaugh A, Smolen J. Methodological aspects and the interpretation of clinical trial data: lessons from the TEAR trial. Rheumatology. 2013;52:409-10.